Background and Aims: Plasminogen activator inhibitor type 1 (PAI-1) is associated with poor prognosis in breast cancer. Transcriptional expression of the . PAI-1 can be controlled by . PAI-1 promoter 4G/5G polymorphism. However, the significance of . PAI-1 promoter 4G/5G polymorphism in breast cancer patients is contentious. To address this controversy, we conducted a meta-analysis for the relationships between . PAI-1 promoter polymorphism and clinicopathological characteristics of breast cancer. Methods: Relevant published studies were identified using a search of PubMed, Embase, and the ISI Web of Science. The effect sizes of . PAI-1 promoter 4G/5G polymorphism on breast cancer risk, lymph node metastasis, histologic grade, and overall survival were calculated by odds ratio (OR) or hazard ratio. The effect sizes were combined using a random-effects model. Results: Individuals with 4G/4G genotype had a higher risk of breast cancer than those with the combined 4G/5G and 5G/5G genotypes (OR = 1.388; . p = 0.031). Breast cancer patients with the 5G/5G genotype displayed lymph node metastasis more than patients with either the combined other genotypes (OR = 1.495; . p = 0.027) or with the 4G/4G genotype (OR = 1.623; . p = 0.018). However, the . PAI-1 promoter 4G/5G polymorphism was not associated with histological grade or overall survival. Conclusions: PAI-1 promoter 4G/5G polymorphism is associated with a relatively increased risk of breast cancer development and lymph node metastasis.
|Number of pages||7|
|Journal||Archives of Medical Research|
|Publication status||Published - 2013 Jan|
- Breast cancer
ASJC Scopus subject areas